Photodynamic therapy using verteporfin-induced minimal change nephrotic syndrome.
OBJECTIVE
To report a case of minimal change nephrotic syndrome (MCNS) after photodynamic therapy using verteporfin.


METHODS
Interventional case report.


METHODS
After four cycles of photodynamic therapy, general weakness with generalized edema developed in an otherwise healthy 66-year-old woman, resulting in dyspnea and ascites. Urinalysis showed heavy proteinuria (4+) with decreased serum total protein and albumin, and increased total cholesterol levels, suggesting nephrotic syndrome. Renal biopsy and pathologic diagnosis were performed.


RESULTS
Renal biopsy revealed normal glomeruli and tubulointerstitium by light microscopy, with no immunoglobin or complement deposition. Transmission electron microscopy showed diffuse effacement of the foot processes of visceral epithelial cells, which is the characteristic finding of minimal change nephrotic syndrome.


CONCLUSIONS
We herein report a case of minimal change nephrotic syndrome after photodynamic therapy using verteporfin.
Kang
Shin W
SW
Department of Internal Medicine, Institute of Kidney Disease, Yonsei University College of Medicine, Sodaemun-gu, Seoul, South Korea.
Kang
Shin J
SJ
Kim
Hyun O
HO
Nam
Eun S
ES
Lee
Jin H
JH
Koh
Hyoung J
HJ
D000368:Aged; D001706:Biopsy; D001798:Blood Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007668:Kidney / Q000473:pathology; D009402:Nephrosis, Lipoid / Q000139:chemically induced* / Q000175:diagnosis; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000009:adverse effects*; D011166:Porphyrins / Q000009:adverse effects*; D011507:Proteinuria / Q000175:diagnosis; D000077362:Verteporfin
D001798:Blood Proteins; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D002784:Cholesterol